Trial reportDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2011
[Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].
Trial report in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- Comparison of Two Botulinum Neurotoxin Type A Preparations (Masport and Dysport) for Upper Face Rhytides: A Randomized Clinical Trial.Aesthetic plastic surgery · 2025Trial
- Sensory Symptoms Associated with Aesthetic Botulinum Toxin A Treatments.Plastic and reconstructive surgery. Global open · 2022Article
- Use of Botulinum Neurotoxin in Ophthalmology.Turkish journal of ophthalmology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor the first time, the effectiveness of Xeomin®, and Dysport® in an dose-ratio of 1:3 treating crow's feet (FWS 2-3) was evaluated in a double-blind randomized pilot study. PATIENTS AND
methodXeomin® (12 units) was compared to Dysport® (36 units) in an intra-individual split-face technique in 22 patients over a period of 4 months. According to the facial-wrinkle-scale (FWS) patients were rated as responders with an improvement of at least 1 point in FWS.
resultsOne month after treatment significantly more than 80% of patients were rated as responders. The different products proved to be equivalent in response rate and effectiveness with no significant difference after 4 weeks and 4 months in statistical analysis. Surprisingly the decrease in FWS of crows' feet at rest was more pronounced.
conclusionThe different botulinum toxin type A formulations proved to be equivalent in effectiveness and tolerability in a dose ratio of 1:3 (Xeomin®: Dysport®) The more pronounced decrease of crow's feet at rest points out the importance of muscle insertion into the skin for the cosmetic result in the periorbital region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.